News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Durable Responses Observed in Recurrent High Grade Glioma (rHGG) with Toca 511 & Toca FC Treatment


Posted on: 10/28/2017

Durable Responses Observed in Recurrent High Grade Glioma (rHGG) with Toca 511 & Toca FC Treatment

Editor's Note:

 This is a presentation about the Toca 511 / Toca FC  trial.   There are 6 long term survivors (4 GBM, 2 AA), ALL of whom had a complete response,  And once they achieve a complete response, NONE had a recurrence.  We never use the word "cured" when talking about a GBM, but having a clear scan for over 3 years makes us think it is possible a few of these patients may have been cured.  It is only a small  % at this time - 43% have some benefit from the treatment, and 20% have a significant response.  Hopefully it will only get better and this may lead to a major breakthrough.

The Musella Foundation was an early supporter of this research (and they acknowledge us on the presentation:)

(The link is to a .pdf file.  The free adobe reader might be needed to view it)

 


 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites